JF
ARQT icon

Jump Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Jump Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.17M Buy
235,471
+185,904
+375% +$4.33M 0.05% 430
2026
Q1 		$1.17M Sell
49,567
-381,335
-88% -$9.73M 0.02% 860
2025
Q4 		$12.5M Buy
430,902
+80,417
+23% +$2.06M 0.15% 157
2025
Q3 		$6.61M Buy
350,485
+335,923
+2,307% +$5.3M 0.08% 323
2025
Q2 		$204K Sell
14,562
-27,438
-65% -$385K ﹤0.01% 1602
2025
Q1 		$657K Buy
42,000
+26,874
+178% +$379K 0.01% 978
2024
Q4 		$211K Buy
+15,126
New +$166K ﹤0.01% 1465
2024
Q3 		– Sell
-151,385
Closed -$1.41M – 1628
2024
Q2 		$1.41M Buy
151,385
+83,787
+124% +$758K 0.03% 688
2024
Q1 		$670K Buy
+67,598
New +$505K 0.02% 1028
2023
Q4 		– Sell
-20,286
Closed -$108K – 1767
2023
Q3 		$108K Buy
+20,286
New +$173K ﹤0.01% 1668
2023
Q2 		– Sell
-42,914
Closed -$472K – 1780
2023
Q1 		$472K Buy
42,914
+2,535
+6% +$36.7K 0.02% 922
2022
Q4 		$598K Buy
+40,379
New +$705K 0.03% 700

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jump Financial's ARQT Position: Q2 2026 in Review

Jump Financial increased its Arcutis Biotherapeutics (ARQT) stake by 375% in Q2 2026, buying an estimated $4.33M and bringing the position to 235,471 shares worth $6.17M. The position accounts for 0.05% of the portfolio, ranked #430.

Jump Financial first reported a position in ARQT in Q4 2022 and has held it in 12 quarters since. The position peaked at $12.5M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Jump Financial held 235,471 shares of Arcutis Biotherapeutics worth $6.17M as of Q2 2026.
  • Jump Financial bought 185,904 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.33M.
  • Arcutis Biotherapeutics made up 0.05% of Jump Financial's portfolio in Q2 2026, its #430 holding.
  • Jump Financial first reported a position in Arcutis Biotherapeutics in Q4 2022 and has held it in 12 quarters since.
  • Jump Financial's Arcutis Biotherapeutics position peaked at $12.5M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.